Global Nuclear Medicine / Radiopharmaceuticals Market worth $5.55 Billion by 2017

 Global Nuclear Medicine / Radiopharmaceuticals Market worth $5.55 Billion by
                                     2017

  PR Newswire

  DALLAS, April 1, 2013

DALLAS, April 1, 2013 /PRNewswire/ --

The Nuclear Medicine/ Radiopharmaceuticals Market  [SPECT/PET Radioisotopes
(Technetium, F-18)], [Beta/Alpha Radiation Therapy (I131, Y-90)],
[Applications (Cancer/Oncology, Cardiac)] & Stable Isotopes (Deuterium, C-13)
 -  Global Trends & Forecast To 2017 analyzes and studies the major market
drivers, restraints, and opportunities in North America, Latin America,
Europe, Asia, and Rest of the World.

Browse

  *142 market data tables
  *44 figures
  *346 pages and an in-depth Table of Content on Nuclear Medicine /
    Radiopharmaceuticals Market

http://www.marketsandmarkets.com/Market-Reports/radiopharmaceuticals-market-417.html

Early buyers will receive 10% customization on this report.

This report studies the global nuclear medicine market over the forecast
period 2012-2017.

The global radiopharmaceutical market was valued at $3.8 billion in 2012 and
is poised to reach $5.5 billion by 2017 at a CAGR of 7.8%.

The radioisotopes market is categorized into diagnostic and therapeutic
applications. The diagnostic market consists of PET and SPECT technologies,
while the therapy market comprises of beta emitters and brachytherapy seeds.
The SPECT market accounted for a major share of the diagnostic segment in
2012. Significant radioisotopes in the SPECT diagnostic market are Tc-99m, Tl-
201, Ga-67, and I-123, while PET market is dominated by F-18, and Rb-82. The
therapy market is led by I-131, Sm-153, Re-186, Y-90, and Lu-177. Alpha
emitters are being developed and considered for cancer treatment, however not
available commercially.

It is estimated that Tc-99m diagnostic procedures are expected to increase by
more than 15% in mature markets of North America, Europe, Japan, the Republic
of Korea, and Oceania between 2010 and 2030, however shortage of Mo-99/Tc-99m
has been a threat to this industry. The scheduled shutdown of the NRU reactor
in 2016 and OSIRIS in France in 2018 is a major risk for manufacturers in the
near future. Companies have increased the production of thallium to meet the
shortage, as it is the most commonly used substitute for technetium-99 in
cardiac-stress tests, conducted to evaluate the functioning of coronary
arteries. Radiopharmaceuticals in neurological applications such as
Alzheimer's disease, Parkinsons disease, and dementia are also being preferred
by practitioners besides conventional treatment. Further, upcoming
radioisotopes such as Ra-223 (Alpharadin) and Ga-68 possess huge potential for
clinical applications.

Increasing use of SPECT and PET scans, technical advancements in equipment and
other factors such as rising awareness of radiopharmaceuticals among
physicians, alpha radioimmunotherapy based targeted cancer treatment, and
ready availability of nuclear medicinemarket from cyclotrons have driven the
market. High cost of devices using radioisotopes, short half-life, lack of
good manufacturing practices, and stringent regulatory approvals are major
hurdles to growth of the market.

North America is the dominant market for diagnostic radioisotopes with close
to half of the market share. The U.S. is the largest consumer market for
radiopharmaceuticals, while Canada is one of the largest producers of Tc-99m.

Processors such as Nordion, Inc., Covidien Plc., and NTP Radioisotopes Pty
Ltd. run reactors that are involved in the irradiation of U-235 to make crude
isotopes. They follow various strategies to achieve sustainable growth, one of
which is shifting to Low Enriched Uranium (LEU) from High Enriched Uranium
(HEU). These key players were mainly involved in strategic agreements and
contracts with other institutes and players, while generator manufacturers
followed several strategies to maintain a sustainable supply chain.

The stable isotopes market was less than $150 million in 2012 and poised to
grow at more than 10% CAGR in the next 5 years. Carbon-13 commanded the
largest share of the global stable isotope market in 2012; however deuterium
and oxygen show tremendous potential to grow in the near future. The market
was dominated by two players, Cambridge Isotope Laboratories (CIL) (U.S.) and
Isotec (Sigma Aldrich) (U.S.) in 2012 jointly contributing more than 90% to
the global revenue.

Buy a copy of this report @
http://www.marketsandmarkets.com/Purchase/purchase_report1.asp?id=417

About MarketsandMarkets

MarketsandMarkets is a global market research and consulting company based in
the U.S. We publish strategically analyzed market research reports and serve
as a business intelligence partner to Fortune 500 companies across the world.

MarketsandMarkets also provides multi-client reports, company profiles,
databases, and custom research services. MarketsandMarkets covers thirteen
industry verticals; including advanced materials, automotives and
transportation, banking and financial services, biotechnology, chemicals,
consumer goods, telecommunications and IT, energy and power, food and
beverages, industrial automation, medical devices, pharmaceuticals
,semiconductor and electronics, aerospace & defense.

We at MarketsandMarkets are inspired to help our clients grow by providing apt
business insight with our huge market intelligence repository.

Contact : Mr.  Rohan North - Dominion Plaza, 17304 Preston Road, Suite
800,Dallas, TX75252 Tel: +1-888-6006-441 Email: sales@marketsandmarkets.com
Visit MarketsandMarkets Blog @ http://www.marketsandmarketsblog.com Connect
with us on LinkedIn @ http://www.linkedin.com/company/marketsandmarkets Visit
our Google plus Profile @ https://plus.google.com/113935125281262465077/posts
 
Press spacebar to pause and continue. Press esc to stop.